News 2024-11-09
Porton’s New Modality Capacity Upgrade Ceremony Successfully Held
On November 7, 2024, the New Modality Capacity Upgrade Ceremony was successfully held in Fengxian, Shanghai, China. Attendees included Mr. Weng Jun，Vice General Manager，Shanghai Hangzhou Bay Economic & Technological Development Co., Ltd., Mr. Bai Yinchun, COO and Senior Vice President of Porton, Ms. Pi Wei, Vice President and Board Secretary of Porton, Ms. Meng Fan, Deputy General Manager of the Sales & Marketing Center of Porton, and Mr. Xie Lihua, Head of the Synthetic Macromolecules Service Department. Together, they witnessed this significant moment of enhancing the production capacity for new modalities at the Fengxian site.
As a leading global CDMO, Porton has proactively responded to market demand by investing in expanding its capabilities in new modality technologies. Since establishing our Tides CDMO service platform, we have provided customers with 'one-stop' services in small nucleic acids, peptides, and conjugated drugs. This includes process development and optimization, toxicology batch production, clinical sample production, structural characterization, analytical method development and validation, stability studies, and global registration of new drugs. With the commissioning of three GMP production workshops for peptides, oligonucleotides, and payload-linkers at the Fengxian site, especially the opening of the OEB 5 High Potency area, Porton's CDMO service platform is now fully equipped to offer global customers comprehensive CMC solutions from preclinical development to drug commercialization.
During the event, our leaders and guests delivered speeches and participated together in the launch ceremony.
"The upgrade and expansion of Porton's
Fengxian site not only enhance production efficiency but also provide strong
support for the development of various new drugs. This initiative will
contribute positively to establishing a hub for industrial innovation and
development in the development zone and achieving high-quality growth,"
said Mr. Weng Jun, Vice General Manager, Shanghai Hangzhou Bay Economic & Technological Development Co., Ltd.
"This capacity upgrade at the Fengxian site marks another important milestone in Porton's ongoing commitment to the peptide and oligonucleotide drug fields. Porton will continue to enhance its technological capabilities and pursue innovations to support the development of innovative drugs for our global customers," said Mr. Bai Yinchun, COO and Senior Vice President of Porton.
"This upgrade will enhance Porton's competitiveness in the global market. Porton remains confident and will seize new opportunities to accelerate the research, development, and production of new modality products, as well as advance business development. Our aim is to offer customers more competitive products and services, while contributing to the growth of regional pharmaceutical industry," said Ms. Pi Wei, Vice President and Board Secretary of Porton.
Finally, under the leadership of Mr. Xie Lihua, Head of the Synthetic Macromolecule Service Department, the group visited the new modality production capacity workshop at the Fengxian site, successfully concluding the day's ceremonial activities.
The completion of the New Modality capacity upgrade not only highlights our technical strength in new modality such as peptides, oligonucleotides, and ADC drugs, but also enables Porton to realize significant business opportunities and breakthroughs with new customers in Europe and the US, further promoting Porton’s globalization.
About Porton Shanghai Fengxian Site
Porton's Shanghai Fengxian site is the company's
core GMP production center in the Yangtze River Delta region, covering an area
of 100 acres. It is equipped with reactors ranging from 10 liters to 6,300
liters, with a total capacity of nearly 100 cubic meters, supporting the mass
production of APIs up to 100 kilograms. We are dedicated to providing customers
with highly efficient and flexible API production of chemical small molecules,
peptides, and oligonucleotides, covering the drug development process from
preclinical stages to commercialization. Additionally, we have received
approval for the marketing of several APIs.
About Porton
Founded in 2005, Porton Pharma Solutions Ltd. is an
internationally recognized pharmaceutical contract development and
manufacturing organization (CDMO) in enabling our global clients to optimize
drug development and manufacturing. We provide customer development and
manufacturing services for Small Molecules, Tides, Biologics and Conjugates (ADCs,
AOCs, PDCs, etc.) from pre-clinical to commercialization. As of June 30, 2024,
we have a proven record for the delivery of more than 3500 projects and
established cooperation with more than 1000 global clients. With our 4300+
skilled employees working across 20+ sites around the globe, Porton is
committed to becoming the most open, innovative and reliable pharmaceutical
service platform in the world and enabling the public’s early access to good
medicines. Porton is publicly listed on the Shenzhen Stock Exchange (Ticker:
300363).
Others
More
News 2025-01-14
Successful GMP Drug Product Delivery by Porton Biologics and Conjugates Platform
Recently, the Porton Biologics and Conjugates Platform successfully completed the GMP contract manufacturing of three batches of sterile drug products for a client at our R&D and production facility in Pudong, Shanghai. This milestone marks a significant step forward for our Biologics and Conjugates CDMO platform—a testament to our unwavering commitment to quality and reliability.
News 2025-01-03
Porton Achieves Higher Scores in the 2024 S & P Global ESG Assessment
Porton Pharma Solutions Ltd. (hereinafter “Porton”) is glad to announce that it scored 44 (out of 100) in the 2024 S&P Global Corporate Sustainability Assessment reflecting an improvement of 6 points over the previous assessment, where scores in all the three dimensions getting improved. (CSA Score as of 27/11/2024).
